History & Physical for Patients Starting TRT

Course Overview

This course establishes a disciplined internal medicine framework for evaluating androgen-naïve patients before testosterone therapy is initiated. Its central message is straightforward but frequently ignored in modern practice: That framework is foundational to Testosteronology® because once testosterone exposure begins, baseline physiology is no longer cleanly available for interpretation. [1-4]

The history and physical (H&P) therefore do much more than support the workup. They determine whether the patient has a convincing androgen-deficiency presentation, whether other diseases are more likely to explain the concern, and whether testosterone is appropriate now, later, or not at all. The clinician who works through that complexity before exposure is practicing better medicine than the clinician who tries to sort it out afterward. [1-7]

Learning Objectives

After completing this course, clinicians should be able to:

➀ Apply a structured internal medicine H&P framework to patients being evaluated for TRT.

➁ Explain why testosterone therapy is not initiated from laboratory values alone and requires symptom correlation plus risk stratification.

➂ Perform a clinically useful HPI, past medical history, psychosocial history, psychiatric history, medication history, family history, and focused review of systems in TRT-seeking patients.

➃ Use the ABCDS™ framework to integrate cardiometabolic, renal, hematologic, psychiatric, and preventive screening into testosterone evaluation.

➄ Identify baseline medical, psychiatric, reproductive, and behavioral risks that should alter timing or appropriateness of TRT initiation.

➅ Recognize when symptoms are more likely driven by sleep, metabolic disease, psychiatric illness, medication effects, or chronic disease than by androgen deficiency itself.

➆ Distinguish low-risk, intermediate-risk, and high-risk patients before testosterone exposure begins.

Video Lesson Takeaways

◉ Testosterone therapy is not initiated from a laboratory value alone. It requires symptom correlation, structured history, physical examination, and meaningful pre-exposure risk stratification.

◉ Many patients seeking TRT have multifactorial disease, and symptoms commonly attributed to testosterone may be driven by sleep, metabolic, psychiatric, medication-related, or behavioral factors.

◉ A serious internal medicine history must include clinical, behavioral, psychiatric, and exposure-based components rather than a narrow symptom inventory.

◉ The ABCDS™ framework keeps testosterone care integrated with glycemic, renal, cardiovascular, hematologic, psychiatric, and preventive medicine.

◉ Physical examination should identify findings that materially strengthen or weaken the case for androgen deficiency rather than functioning as a ceremonial step.

◉ Ancillary studies should clarify risk before therapy, not replace clinical reasoning or create false diagnostic confidence.

◉ Risk stratification determines whether TRT is appropriate now, later, or not at all.

◉ One of the most important clinical skills in testosterone medicine is recognizing when testosterone is not the correct first intervention.

➀ Foundational Principle

Testosterone therapy is not initiated from a lab value alone. It requires clinical symptom correlation, comprehensive history, targeted physical examination, and risk stratification before exposure begins. That principle sounds basic, but many of the most consequential failures in TRT practice begin when it is abandoned in favor of treatment momentum, patient demand, or number-driven prescribing. [1-6]

A low or borderline testosterone result can coexist with obesity, sleep deprivation, depression, diabetes, opioid exposure, chronic illness, circadian disruption, and medication-related sexual dysfunction. Several of these conditions, particularly obesity, sleep deprivation, and metabolic disease, can also physiologically suppress endogenous testosterone production. I The clinician’s responsibility is not to react to the number first. The responsibility is to determine whether the history, phenotype, and broader medical context support a real androgen-deficiency syndrome strongly enough that testosterone remains the correct next step after the full evaluation is finished. [1-9]

Once exposure to exogenous testosterone begins, fertility may be altered, hematologic behavior may change, symptom interpretation becomes more complicated, and retrospective diagnostic clarity often becomes poorer rather than better. Good clinicians therefore treat the pre-therapy evaluation as the cleanest diagnostic window they will get. Patients who have already been exposed to testosterone or anabolic steroids require a different diagnostic framework, which is addressed separately in the following course.

➁ Standard Internal Medicine H&P Framework

The H&P should be approached with the same seriousness used in any other internal medicine decision that has long-horizon implications. The chief concern reflects the patient’s reason for coming in, often fatigue, low libido, erectile dysfunction, poor recovery, mood decline, body composition change, or reduced vitality. Those concerns are real and clinically relevant, but they are not all equally specific. Their meaning depends on what the rest of their history reveals. The chief concern should ideally be recorded in the patient’s own words as a brief one-line statement describing why they sought evaluation. [1-6]

The history of present illness should be chronological and diagnostic, not merely descriptive. When the history is weak or incomplete, diagnostic confidence in androgen deficiency becomes correspondingly weaker. Onset, duration, progression, severity, functional impact, associated sexual symptoms, sleep disturbance, mood changes, exercise tolerance, and prior evaluation. The history should also actively differentiate true androgen deficiency from symptoms driven by lifestyle stress, sleep disruption, substance use, chronic disease, or psychiatric conditions.

Past medical history must be treated as a risk map rather than a checkbox exercise. Hypertension, coronary disease, heart failure, diabetes, prediabetes, obesity, thyroid disease, renal disease, hepatic disease, sleep apnea, and malignancy history are not parallel concerns. They directly shape whether testosterone initiation is safe, premature, or inappropriate in the current state. Psychiatric and behavioral history deserves the same seriousness. Depression, anxiety, bipolar spectrum illness, impulsivity, ADHD, body image disturbance, and prior psychiatric medication exposure may alter symptom interpretation, adherence, and treatment safety. Early life medical history can occasionally reveal contributing factors such as autoimmune disease, chronic corticosteroid exposure, or childhood illness that later affects endocrine function. [1,6-9]

Medication and exposure history is equally important because many common therapies distort the clinical picture. SSRIs, opioids, glucocorticoids, antipsychotics, prior testosterone exposure, anabolic steroids, supplements, peptides, and performance agents all influence the physiology the clinician is trying to interpret. Medication review can also reveal previously unrecognized diagnoses because long-term prescriptions often reflect underlying diseases patients may forget to mention.

Family history should include early cardiovascular disease, metabolic syndrome, thrombophilia, prostate or breast cancer, and major psychiatric patterns. A thorough psychosocial history may include occupational stress, shift work, childhood adversity, trauma exposure, and behavioral patterns that influence hormonal health and symptom interpretation.

A focused review of systems then integrates the concern across endocrine, cardiovascular, respiratory, neurologic, psychiatric, reproductive, and hematologic domains. The review of systems should also specifically assess urinary and prostate-related symptoms, including lower urinary tract symptoms and prior PSA evaluation when relevant. In strong clinical work, none of these elements are filler. Each one either strengthens or weakens the case for TRT. [1-7]

➂ Physical Examination

The physical examination begins with the ABCDS™ system because testosterone evaluation must remain integrated with primary medical care rather than isolated as “hormone optimization.” That is one of the most important teaching corrections in the course outline. Testosterone care that is detached from glycemic health, blood pressure, renal risk, cardiovascular screening, hematologic baseline, and broader systemic screening is not more efficient care. It is lower quality care. The ABCDS™ framework emerged from clinical observation that cardiometabolic and renal disease were major drivers of long-term morbidity in androgen-exposed populations. [1,7,9]

Within ABCDS™, glycemic assessment should identify insulin resistance and metabolic disease that may be contributing to fatigue, adiposity, low libido, and reduced vitality. Blood pressure and renal assessment should establish whether vascular burden and early nephropathy are already present before androgen exposure begins. Cardiovascular screening should remain alert to structural and ischemic risk in the right patient rather than assuming that age or outward fitness excludes meaningful disease.

Hematologic assessment should identify baseline erythropoietic behavior, iron status, and factors that may increase susceptibility to androgen-induced erythrocytosis. The systemic domain extends the examination into mental health, age-appropriate cancer screening, and preventive care, all of which belong in serious testosterone medicine. Clinicians should distinguish androgen-induced erythrocytosis from true hematologic disease and avoid mislabeling the condition as polycythemia vera. Environmental factors such as chronic high-altitude residence may also contribute to elevated baseline red blood cell counts.[1-6]

The standard physical examination then makes the framework clinically concrete. Vital signs should include blood pressure, heart rate, BMI, waist circumference, and oxygen saturation. General appearance should assess body composition, adiposity, lean mass, and signs of chronic disease rather than collapsing the impression into “fit” or “unfit.” Cardiovascular examination should assess murmurs, peripheral circulation, and signs of heart failure. Respiratory examination should remain alert to sleep apnea phenotype and work of breathing. Endocrine and reproductive examination should include testicular size and consistency, gynecomastia, hair distribution, and physical clues that either support or weaken a true androgen-deficiency phenotype. Neurologic and psychiatric assessment should include cognition, mood, affect, and behavior. The point is not to perform a ritual exam. The point is to gather findings that materially change the story. [1-9]

➃ Ancillary Diagnostic Studies (Pre-Therapy Risk Stratification)

Ancillary studies should be ordered to answer specific risk questions before therapy, not to replace clinical thinking or create a false sense of comprehensiveness. Cardiovascular assessment may include coronary artery calcium scoring, coronary CT angiography, echocardiography, cardiac MRI in select circumstances, or arrhythmia monitoring when the risk profile justifies deeper evaluation. These tests are not routine for every patient, but the outline is correct to include them because some TRT-seeking patients carry structural or ischemic risk that should be identified before exposure rather than rediscovered after a complication. Preventive cardiovascular imaging may be appropriate in selected middle-aged patients with risk factors even when overt disease has not yet been diagnosed. [1,2,7]

Blood pressure should be confirmed with reliable measurement strategies, including ambulatory monitoring when indicated. Renal assessment should include creatinine, eGFR, and urinary albumin evaluation. Metabolic testing should clarify glycemic status and lipids. Modern cardiometabolic therapies such as GLP-1 receptor agonists, dual incretin agents, and SGLT2 inhibitors have significantly expanded treatment options for patients with metabolic risk. Sleep evaluation should include screening for obstructive sleep apnea and formal sleep study when appropriate. Reproductive planning must be addressed before therapy begins, not after suppression occurs. Fertility preservation options should be discussed before treatment when future childbearing remains important to the patient. [1-8]

Pre-therapy testing can help define risk, not accumulate data. When clinicians order with intention, testing sharpens the decision. When clinicians order indiscriminately, it adds noise without improving judgment.

➄ Clinical Risk Stratification Before TRT Initiation

Risk stratification is where symptom interest is translated into medical judgment. The clinician should first identify absolute contraindications, then identify relative risks that require optimization, and then classify the patient as low risk, intermediate risk, or high risk before therapy begins. That sequencing forces the clinician to think in terms of safety and timing rather than in terms of eligibility. Clinicians should also recognize that many patients seeking TRT have modifiable drivers such as obesity, sleep disruption, or metabolic disease that may warrant treatment before androgen therapy is initiated. [1-6]

Low-risk patients are those whose symptom pattern is convincing, whose background does not raise major competing concerns, and whose baseline evaluation does not reveal a reason to defer. Intermediate-risk patients often represent the majority of real-world cases. High-risk patients are those in whom immediate therapy would be medically irresponsible without further workup, optimization, or co-management. [1-9]

The critical idea is that TRT is not being denied arbitrarily when it is delayed. It is being timed appropriately. Clinicians who skip this step often tell themselves they are helping quickly, when in fact they are exposing patients before the major diagnostic and safety questions have been answered.

➅ Redirection of Diagnosis

Redirection of diagnosis is one of the most important skills in this course because many TRT-seeking patients do not primarily have androgen-mediated disease. They have real symptoms, but the dominant drivers may be sleep apnea, obesity, insulin resistance, psychiatric illness, cardiovascular strain, chronic disease, medication effects, or some combination of these. [1,6,8]

When that is the case, the correct move is not testosterone by default. It is a better diagnosis. That may mean optimizing sleep, addressing metabolic disease, treating psychiatric conditions, reducing cardiovascular risk, or adjusting medications. Many patients improve meaningfully when those drivers are addressed directly, even without androgen therapy. The disciplined clinician therefore asks not only whether testosterone could help, but whether testosterone is the best first intervention given what the H&P have already shown. In some cases, improvement in sleep quality, weight reduction, or management of cardiometabolic disease may partially restore endogenous testosterone production.

Low-quality TRT practice often fails here. It mistakes patient interest in testosterone for proof that testosterone is the missing therapy. Better medicine uses the pre-therapy evaluation to decide when symptoms are endocrine, when they are not, and when the problem is too mixed to justify immediate exposure.

➆ Key Teaching Points for Clinicians

TRT is a deliberate medical intervention, not a shortcut to symptom relief. The H&P remains the cornerstone of diagnosis. Many patients seeking TRT have multifactorial disease and misattributed symptoms, and that is precisely why evaluation must remain broad enough to capture metabolic, psychiatric, cardiovascular, reproductive, and behavioral drivers rather than collapsing everything into hormone language. [1-9]

COURSE SUMMARY

Course 4 establishes that the H&P are the foundation of safe testosterone decision-making in androgen-naïve patients. Testosterone therapy must be supported by symptom correlation, structured clinical evaluation, and meaningful risk stratification before exposure. The ABCDS™ framework ensures that testosterone care remains integrated with broader medical care rather than isolated from it. The defining clinical skill is knowing when the patient is not yet medically ready for it, and when another diagnosis deserves to be treated first.

REFERENCES

Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. doi:10.1016/j.juro.2018.03.115
Male hypogonadism. In: EAU Guidelines on Sexual and Reproductive Health. Arnhem, The Netherlands: European Association of Urology; 2024.
De Silva NL, Papanikolaou N, Grossmann M, et al. Male hypogonadism: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2024;12(10):761-774. doi:10.1016/S2213-8587(24)00199-2
Bhasin S, Snyder PJ. Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism. N Engl J Med. 2025;393(6):581-591. doi:10.1056/NEJMra2404637
Qaseem A, Horwitch CA, Vijan S, Etxeandia-Ikobaltzeta I, Kansagara D. Testosterone treatment in adult men with age-related low testosterone: a clinical guideline from the American College of Physicians. Ann Intern Med. 2020;172(2):126-133. doi:10.7326/M19-0882
Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102(3):1067-1075.
Khera M, Adaikan G, Buvat J, et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation for Sexual Medicine. J Sex Med. 2016;13(12):1787-1804.
Morgentaler A, Khera M, Maggi M, Zitzmann M, Finkelstein JS. Who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014;11(7):1636-1645. doi:10.1111/jsm.12556.

Diagnostic Decision Making: History and Physical for Patients Starting TRT